Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/03/20
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2020 Results - Quick Version Earnings Call TranscriptSeeking Alpha • 11/02/20
Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® TechnologyPRNewsWire • 10/06/20
Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) AmyloidosisPRNewsWire • 09/10/20
Halozyme Therapeutics (HALO) Down 1.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/09/20
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/11/20
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Lag EstimatesZacks Investment Research • 08/10/20
Halozyme Reports Significant Recent Achievements And Second Quarter 2020 ResultsPRNewsWire • 08/10/20
Halozyme Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast CancerPRNewsWire • 06/29/20
Halozyme To Participate In The BMO 2020 Prescriptions For Success Healthcare ConferencePRNewsWire • 06/17/20
Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual CongressPRNewsWire • 06/13/20
Why Is Halozyme Therapeutics (HALO) Up 1% Since Last Earnings Report?Zacks Investment Research • 06/10/20
Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple MyelomaPRNewsWire • 06/04/20